<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971358</url>
  </required_header>
  <id_info>
    <org_study_id>1461/2016</org_study_id>
    <nct_id>NCT02971358</nct_id>
  </id_info>
  <brief_title>Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer</brief_title>
  <official_title>Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most common non-skin cancer diagnosed among men and the second leading&#xD;
      cause of male cancer deaths in the United States. In 2013, it is estimated that 29,270 men&#xD;
      have died from prostate cancer. Although radiation and surgery are quite effective for&#xD;
      localized disease, there is no effective cure for men who present with metastatic prostate&#xD;
      cancer as the 5-year relative survival rate is only 28%.&#xD;
&#xD;
      Currently, androgen deprivation therapy (ADT) via medical or surgical castration is the&#xD;
      standard first-line therapy in men with metastatic disease but castration-recurrent prostate&#xD;
      cancer (CRPC) eventually emerges with a median time of 18-24 months. Once CRPC develops,&#xD;
      secondary hormonal manipulation, chemotherapy, and immunotherapy are marginally effective.&#xD;
&#xD;
      Given the dismal prognosis of metastatic prostate cancer, new ideas and novel approaches must&#xD;
      be explored to improve the clinical outcome. In this regard, recently emerging data suggest&#xD;
      that local tumor control may enhance the effectiveness of subsequent systemic therapies.&#xD;
      Therefore, in this proposal, the investigators have designed a Phase I/II study in which they&#xD;
      will prospectively evaluate the safety and feasibility of cytoreductive prostatectomy in men&#xD;
      with newly diagnosed mPCa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of perioperative complications within 90 days after surgery (Clavien-Dindo-classification)</measure>
    <time_frame>90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start androgen deprivation therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced and Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radical prostatectomy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy</intervention_name>
    <description>Standard radical prostatectomy with extended lymph node dissection is performed.</description>
    <arm_group_label>Radical prostatectomy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of the prostate&#xD;
&#xD;
          -  Very high risk PCA (PSA ≥ 20 oder Gleason Score ≥ 8 oder ≥ cT3) and/or&#xD;
             oligometastasierte PCA (T any N positive M any, oder T any N any M positive)&#xD;
&#xD;
          -  ≤5 bone metastasis&#xD;
&#xD;
          -  ≤75 years&#xD;
&#xD;
          -  Ability for informed consent&#xD;
&#xD;
          -  Clinically no infiltration into the rectum or pelvic wall&#xD;
&#xD;
          -  Clinically no visceral metastasis&#xD;
&#xD;
          -  Male, &gt;18 Jahre&#xD;
&#xD;
          -  Fit for surgery&#xD;
&#xD;
          -  ECOG Performance Status 0 oder 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male, &lt; 18 Jahre&#xD;
&#xD;
          -  &gt; 5 bone metastasis&#xD;
&#xD;
          -  &gt; 75 years&#xD;
&#xD;
          -  No ability for informed consent&#xD;
&#xD;
          -  Clinically infiltration into the rectum or pelvic wall&#xD;
&#xD;
          -  Not fit for surgery&#xD;
&#xD;
          -  Clinically visceral metastasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Grubmüller, MD</last_name>
      <phone>004314040026150</phone>
      <email>bernhard.grubmueller@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Bernhard Grubmüller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

